1. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey
- Author
-
Claudio, Velati, Luisa, Romano, Laura, Fomiatti, Lorella, Baruffi, Alessandro Remo Zanetti, Research Group: Sciariada, Simti L., Lobbiani, L., Prati, D., Marconi, M., Ravagnani, E., Rossi, E., Rossini, S., Bellavita, P., Moroni, G. A., Bodini, U., Pagliaro, P., Azzario, F., Rossi, D., Sciorelli, G., Salvaneschi, L., Cambie, G., Marini, M., Pizzoccolo, G., Gazzola, G. B., Peres, E., Mariottini, C., Graziani, G., Baicchi, U., Palla, P., Vacri, L., Strada, P., Miceli, M., Iudicone, P., Girelli, Gabriella, Ursitti, A., De Silvestro, G., Gentile, R., Di Paola, P., Manca, M., Martinelli, L., Bonomo, P., Calabrese, S., Pistolese, G., Aprili, G., Bressan, F., Ripamonti, M., Catalano, A., Gallerano, P., Giacalone, I., Fiorilla, A., Giannotti, G., Cantella, R., Di Persia, M. G., Esposito, V., Sardella, C., Di Monte, D., Bajorek, M., Reina, A., Silvani, C. M., Piani, M., Salvoni, G., De Felice, L., Macri, M., De Palma, M., Vecchi, C., Belloni, M., Bettini, C., Ghiazza, P., De Santis, D., Di Mauro, L., Antoncecchi, S., Rinaldi, C., Allegreita, G., Siracusano, L., Adami, R., Lanteri, M., Mazzei, C., Tagariello, G., Gajo, G. B., Berti, P., Giordano, C., Palazzesi, G., Del Gusto, B., Pavone, A., Vacchini, M., Tomasini, A., Vaselli, G., Fiorin, F., Bresolin, G., Bertola, F., Testa, D., Semino, G., Tomasini, I., Zucchelli, P., Chicchi, R., Peano, G., Franchi, D., Sabelli, M., Miloro, G., Di Gregorio, P., Reimondo, P., Cimino, G., Tripodi, G., Borzini, P., Tarditi, M., Cocchi, T., Pata, V., Santarelli, R., Geremicca, W., Minerva, A., Maccarione, F. P., Solanda, F., Rivasi, P., Carubia, F., Prinoth, O., Ostuni, A., Bossio, M., Maggiotto, A., Valentino, F., Puzzonia, P., and Source Musto, C.
- Subjects
Adult ,Male ,Hepatitis B virus ,Genotype ,Hepacivirus ,Hepatitis C virus ,Immunology ,Blood Donors ,HIV Infections ,medicine.disease_cause ,Virus ,Flaviviridae ,Orthohepadnavirus ,Risk Factors ,Seroepidemiologic Studies ,medicine ,Humans ,Mass Screening ,Immunology and Allergy ,Aged ,biology ,business.industry ,HIV ,virus diseases ,Hematology ,Middle Aged ,Hepatitis B ,biology.organism_classification ,medicine.disease ,Hepatitis C ,Virology ,digestive system diseases ,Italy ,Hepadnaviridae ,Virus Diseases ,Health Care Surveys ,Blood Banks ,Female ,Morbidity ,Safety ,business ,Risk Reduction Behavior - Abstract
BACKGROUND: Nucleic acid testing (NAT) for hepatitis C virus (HCV) and human immunodeficiency virus (HIV) has been implemented in several European countries and in the United States, while hepatitis B virus (HBV) NAT is still being questioned by opinions both in favor and against such an option, depending on the HBV endemicity, health care resources, and expected benefits. STUDY DESIGN AND METHODS: This survey was aimed to assess the NAT impact in improving the safety of blood supply in Italy, 6 years after implementation. The study involved 93 Italian transfusion centers and was carried out in 2001 through 2006. A total of 10,776,288 units were tested for the presence of HCV RNA, 7,932,430 for HIV RNA, and 3,405,497 for HBV DNA, respectively. RESULTS: Twenty-seven donations or 2.5 per million tested were HCV RNA–positive/anti-HCV–negative; 14 or 1.8 per million units tested were HIV RNA–positive/anti-HIV–negative; and 197 or 57.8 per million donations tested were HBV DNA–positive/hepatitis B surface antigen–negative. Of the latter, 8 (2.3/106) were collected from donors in the window phase of infection and 189 (55.5/106) from donors with occult HBV. Sixty-eight percent of the latter donors had hepatitis B surface antibody, 74.5 percent of whom with concentrations considered protective (≥10 mIU/mL). CONCLUSION: NAT implementation has improved blood safety by reducing the risk of entering 2.5 HCV and 1.8 HIV infectious units per million donations into the blood supply. The yield of NAT in detecting infectious blood before transfusion was higher for HBV than for HCV or HIV. However, the benefit of HBV NAT in terms of avoided HBV-related morbidity and mortality in blood recipients needs to be further evaluated.
- Published
- 2008
- Full Text
- View/download PDF